Answers are grounded in this paper and cite their sources.
Introduction Cholangiocarcinoma (CCA) is a rare, aggressive malignancy with poor prognosis. Long non-coding RNA (LncRNA) are noncoding transcripts that play a role in transcriptional, post-transcriptional and epigenetic regulation. Dysregulated LncRNA expression has been associated with adverse oncologic outcomes and may serve as a prognostic biomarker in CCA. This systematic review and meta-analysis evaluated the prognostic impact of LncRNA expression among patients with CCA. Methods A systematic search of PubMed, Embase, and Scopus was performed using Boolean search terms and Medical Subject Headings for bile duct neoplasms, cholangiocarcinoma, and long non-coding RNA. Random-effects meta-analysis was used to evaluate the association of LncRNA expression with overall survival (OS) and disease-free survival (DFS). Results Thirty-two studies including 1622 patients met inclusion criteria; 53.2% of patients were male. Increased LncRNA expression was associated with worse OS (HR, 1.70; 95% CI, 1.53–1.91; P<.001) and DFS (HR, 2.42; 95% CI, 1.30–4.50; P<.001). The pooled area under the curve for LncRNA-based prognostic models was 0.86 (95% CI, 0.77–0.95; I²=85.6%; P<.000, suggesting good prognostic discrimination. Funnel plots and Egger’s tests demonstrated evidence of publication bias for OS (P = .03) and DFS (P = .013). In sensitivity analyses excluding smaller studies, the pooled effect estimates remained similar. Conclusion LncRNA may serve as promising as prognostic biomarkers in patients with cholangiocarcinoma. Large-scale prospective studies are needed to validate its clinical relevance before routine clinical implementation. Systematic review registration https://www.crd.york.ac.uk/PROSPERO/view/CRD420251103592 , identifier CRD420251103592.
No takes yet. Share an insight, caveat, or question.
Dawood et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: